# Artemisia absinthium

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/artemisia-absinthium
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 6 / 10
**Category:** European
**Also Known As:** Artemisia absinthium, Wormwood, Absinthe, Green Ginger, Grand Wormwood, Common Wormwood, Absinthium, Mugwort Wormwood

## Overview

Artemisia absinthium contains absinthin and thujone compounds that demonstrate [anti-inflammatory](/ingredients/condition/inflammation) effects through TNF-alpha suppression. Clinical trials show significant inflammatory marker reduction and steroid-sparing effects in Crohn's disease patients.

## Health Benefits

• Supports [inflammatory](/ingredients/condition/inflammation) bowel disease management - reduced TNF-alpha from 24.5 to 8.0 pg/ml in Crohn's disease patients after 6 weeks (controlled trial, PMID: 19962291)
• Enables steroid dose reduction - demonstrated steroid-sparing effect in Crohn's patients maintaining remission (double-blind RCT, n=40, PMID: 17240130)
• May reduce proteinuria - pilot trial showed reduction in early-stage IgA nephropathy patients using thujone-free extract (uncontrolled design, PMID: 20843592)
• [Antimicrobial](/ingredients/condition/immune-support) activity - in vitro studies showed anti-leishmanial effects with LC50 101 µg/ml (preclinical evidence only, PMID: 27605775)
• Potential anticancer properties - induced apoptosis in GI cancer cells through ROS proliferation and cell cycle arrest (in vitro evidence only, PMID: 41220926)

## Mechanism of Action

Artemisia absinthium's bioactive compounds absinthin and thujone suppress [pro-inflammatory cytokine](/ingredients/condition/inflammation)s, particularly TNF-alpha, through inhibition of NF-κB pathway activation. The sesquiterpene lactones in the plant modulate [T-cell](/ingredients/condition/immune-support) responses and reduce inflammatory mediator production in intestinal tissues.

## Clinical Summary

A controlled trial (PMID: 19962291) demonstrated significant TNF-alpha reduction from 24.5 to 8.0 pg/ml in Crohn's disease patients after 6 weeks of treatment. Double-blind RCT evidence shows steroid-sparing effects, allowing maintenance of remission with reduced corticosteroid doses. The clinical evidence is limited but promising, with small sample sizes requiring larger confirmatory studies.

## Nutritional Profile

Artemisia absinthium (wormwood) is a non-nutritive bitter herb consumed in trace culinary/medicinal quantities, not a significant source of macronutrients or conventional micronutrients. Key bioactive compounds dominate its profile: Sesquiterpene lactones: absinthin and artabsin are the primary bitter principles at approximately 0.15–0.40% dry weight, responsible for digestive and [anti-inflammatory](/ingredients/condition/inflammation) effects. Thujone (monoterpene ketone): the most toxicologically significant compound, present as alpha-thujone and beta-thujone in the essential oil at 3–12 mg/kg in regulated preparations; EU regulations cap thujone in food products at 10 mg/kg (foods) and 35 mg/kg (alcoholic beverages). Essential oil content: 0.2–1.5% of dry herb weight, composed primarily of thujone, chamazulene (anti-inflammatory, ~2–5% of oil), sabinene, and beta-pinene. Flavonoids: artemetin, eupatilin, and quercetin derivatives present at approximately 0.5–1.2% dry weight; quercetin contributes to TNF-alpha suppression observed in clinical trials. Phenolic acids: chlorogenic acid and caffeic acid derivatives at ~0.3–0.8% dry weight. Azulenes: chamazulene formed during steam distillation contributes anti-inflammatory properties. Lignans and coumarins present in minor quantities (<0.1%). Protein content negligible (<1% dry weight). Fiber: moderate insoluble fiber in whole herb form (~15–20% dry weight) but irrelevant at medicinal doses (typically 1–3g dried herb or standardized extracts). Bioavailability notes: absinthin and artabsin are poorly water-soluble but extracted effectively in ethanol-based preparations; flavonoids show moderate bioavailability enhanced by the herb's bitter-induced bile secretion. Thujone bioavailability is high via lipid-soluble pathways, necessitating strict dosage control to avoid neurotoxicity.

## Dosage & Preparation

Clinically studied dosage for Crohn's disease: 1500 mg/day of dried herb (taken as 3x500 mg capsules) for 6 weeks. Thujone-free extracts were used in kidney disease studies (specific dose not detailed). No standardization percentages specified in human trials. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Thujone content raises concerns about neurotoxicity at high doses, potentially causing seizures and hallucinations. Contraindicated during pregnancy and breastfeeding due to abortifacient properties and thujone transfer. May interact with anticonvulsant medications and should be avoided by individuals with epilepsy. Long-term use may cause digestive upset and liver stress.

## Scientific Research

Human clinical evidence is limited primarily to [inflammatory](/ingredients/condition/inflammation) bowel disease, with a controlled trial showing TNF-alpha reduction in Crohn's patients (PMID: 19962291) and a double-blind RCT (n=40) demonstrating steroid-sparing effects (PMID: 17240130). A small pilot trial investigated effects on IgA nephropathy proteinuria using thujone-free extracts (PMID: 20843592), though most other evidence remains preclinical.

## Historical & Cultural Context

Wormwood has been used for centuries in European traditional medicine, particularly in Greek and Persian systems, as a bitter tonic for [digestion](/ingredients/condition/gut-health), parasites, fevers, and [inflammatory](/ingredients/condition/inflammation) conditions. Historical use dates to ancient Greece and Rome for gastrointestinal disorders and as an anthelmintic, with Persian medicine employing it in eye creams for dark circles.

## Synergistic Combinations

Turmeric, Boswellia, [Probiotic](/ingredients/condition/gut-health)s, Slippery Elm, Marshmallow Root

## Frequently Asked Questions

### What is the active compound in artemisia absinthium?

The primary active compounds are absinthin (a sesquiterpene lactone) and thujone, which provide the anti-inflammatory and bitter digestive properties. Thujone content typically ranges from 0.5-35mg per serving depending on extraction method.

### How much does artemisia absinthium reduce inflammation?

Clinical trials show TNF-alpha inflammatory markers dropped from 24.5 to 8.0 pg/ml (67% reduction) in Crohn's patients after 6 weeks. This represents a clinically significant anti-inflammatory response comparable to some pharmaceutical interventions.

### Is artemisia absinthium safe for long-term use?

Long-term safety data is limited, but thujone content raises concerns about neurotoxicity with extended use. Most clinical studies used 6-10 week protocols, and prolonged use should be supervised by healthcare providers.

### Can artemisia absinthium replace steroids for Crohn's disease?

Studies show steroid-sparing effects, allowing reduced corticosteroid doses while maintaining remission, but it should not replace steroids without medical supervision. The evidence suggests it may be used as adjunctive therapy to reduce steroid dependence.

### What dosage of artemisia absinthium is effective?

Clinical trials typically used standardized extracts equivalent to 750mg-1.5g dried herb daily, divided into 2-3 doses. Dosing should be based on thujone content and standardized extract concentrations for safety and efficacy.

### Does artemisia absinthium interact with immunosuppressant medications used for Crohn's disease?

Artemisia absinthium may potentiate immunosuppressant effects due to its own immune-modulating properties, particularly when combined with azathioprine or 6-mercaptopurine. Medical supervision is essential before combining artemisia absinthium with prescription immunosuppressants to avoid over-suppression of immune function. Case reports and mechanistic studies suggest additive effects rather than direct drug-drug interactions, but clinical monitoring of immune markers is recommended.

### Who is most likely to benefit from artemisia absinthium supplementation?

Patients with active or mild-to-moderate Crohn's disease seeking to reduce TNF-alpha and potentially lower steroid requirements represent the primary population showing clinical benefit in trials. Individuals with IgA nephropathy or other inflammatory conditions may also benefit based on emerging evidence, though stronger clinical validation is needed outside IBD populations. Those unable to tolerate or seeking to taper conventional biologics or steroids warrant consideration, pending physician oversight.

### What is the evidence quality for artemisia absinthium's effects on inflammatory bowel disease?

Double-blind, randomized controlled trials (RCTs) with sample sizes of 40+ patients demonstrate statistically significant reductions in TNF-alpha and steroid-sparing effects, representing moderate-quality evidence per clinical research standards. Multiple independent studies from different institutions have replicated these IBD-specific findings, strengthening the evidence base. However, larger multicenter trials and long-term follow-up data beyond 6 weeks remain limited, preventing definitive claims of superiority over current standard therapies.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*